By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
latest_posts
- 1
Cheetos and Doritos to launch new versions without artificial dyes - 2Single women risk rape and exploitation in search for better life in Europe
- 3Elanco's drug gets emergency nod to treat deadly flesh-eating parasite in cats
- 4This star-forming galaxy is blowing out powerful winds topping 2 million mph
- 5See the first close-up photos of the moon from NASA's Artemis II mission
- Figure out how to Arrange a Fair Settlement with the Assistance of a Fender bender Legal counselor
- Kids may be more likely to get the new ‘Cicada’ variant of Covid-19, scientists say. Here’s what to know about BA.3.2
- Top Breakfast Food: What's Your Morning Enjoyment?
- Vote In favor of Your Favored Web based Dating Application
- Journeys That could only be described as epic: Delightful Voyage Lines All over the Planet
- NASA's moon mission has begun — here's what's ahead for the Artemis II astronauts
- Activists: Venezuela released just nine prisoners despite promise
- Instructions to Improve Your Mental Exploration with Cutting edge Measurements
- The most effective method to Pick the Right Old Consideration Administration: Key Contemplations
